NCT05446857View on ClinicalTrials.gov

Glecaprevir/Pibrentasvir for the Treatment of PTSD

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2023

Primary Completion Date

April 15, 2024

Study Completion Date

April 15, 2024

Conditions
PTSD
Interventions
DRUG

Glecaprevir / Pibrentasvir Pill

Glecaprevir 100 mg/Pibrentasvir 40 mg, 3 oral tablets once daily for 8 weeks.

Trial Locations (1)

05009

White River Junction VAMC, White River Junction

All Listed Sponsors
lead

White River Junction Veterans Affairs Medical Center

FED